company has reiterated not wanting to commercialise the drugs.
so. phase 1 for PSK9i is starting end of this year into first half 2022.
if things continue to go well and prelim data holds even party.
this will be bought out this time next year.
how they carve out the chol drug from the tbi drug is a good problem to have.
I see this as a 12mo play for multibagger.
bull case, page-110
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
